- Home
- ZIP vs RZLT Comparison
ZIP vs RZLT Comparison
Compare ZIP & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZIP | RZLT |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.9M | 352.1M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ZIP | RZLT |
|---|---|---|
| Price | $4.29 | $3.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $4.75 | ★ $10.10 |
| AVG Volume (30 Days) | 624.2K | ★ 1.3M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $448,952,000.00 | N/A |
| Revenue This Year | $2.98 | N/A |
| Revenue Next Year | $5.06 | $2,482.28 |
| P/E Ratio | $8.16 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.65 | $1.07 |
| 52 Week High | $5.61 | $11.17 |
Technical Indicators
Market Signals| Indicator | ZIP | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 46.61 |
| Support Level | $3.61 | $3.69 |
| Resistance Level | $4.60 | $4.09 |
| Average True Range (ATR) | 0.31 | 0.28 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 51.33 | 42.69 |
Price Performance
Historical ComparisonAbout ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace that connects job seekers and employers through an AI-powered platform. The company provides recruiting solutions that help employers identify and hire qualified candidates while enabling job seekers to discover relevant job opportunities through intelligent matching and recommendation tools.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.